GW Pharma's New Compound GWP42006 Fails Initial Trial Testing | CashCropToday
0 Shares 184 Views

GW Pharma’s New Compound GWP42006 Fails Initial Trial Testing

February 22, 2018
184 Views

On February 21, 2018 GW Pharmaceuticals PLC (Nasdaq:GWPH) (“GW,”) announced that a Phase 2a proof of concept study of a pipeline compound GWP42006 in adult patients with focal seizures did not meet its primary endpoint.  The trial was conducted outside the United States, primarily in Eastern Europe.  In the trial’s preliminary results, both active and placebo studies showed similar reductions in focal seizures of approximately 40 percent.  The extent of the placebo response was substantially greater than that seen in published studies of other treatments in similar patient populations and GW is now working to understand the potential reasons for the results.

Compound GWP42006 had, in the past, shown anti-epileptic properties across a range of in vitro and in vivo models of epilepsy.  GW plans to continue exploring potential development opportunities for this compound in the field of epilepsy.  In parallel with the failed study, the company has also been evaluating GWP42006 in clinical models on ASD (Autism) with promising results for cognitive and social symptoms as well as repetitive behavior.  However, according to company executives, GW’s top priority in 2018 will remain Epidiolex which is currently under regulatory review in the U.S. and Europe and is expected to launch later this year in the U.S.  Epidiolex has been shown to effectively treat symptoms in a variety of rare epileptic conditions.

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas.

You may be interested

Colorado Passes Bill to Allow Public Companies to Invest into Cannabis  Businesses
Politics
6 views
Politics
6 views

Colorado Passes Bill to Allow Public Companies to Invest into Cannabis Businesses

Sam Rosenberg - May 23, 2018

Colorado has just passed a House Bill 18-1011 which will allow publicly trade companies in the U.S. to invest and hold medicinal or recreational cannabis cultivation, processing,…

Phoenix Tears Signs Agreement to Offer Rick Simpson Oil CBD Products at 7-Eleven Stores in 2018
Manufacturing
9 views
Manufacturing
9 views

Phoenix Tears Signs Agreement to Offer Rick Simpson Oil CBD Products at 7-Eleven Stores in 2018

Sam Rosenberg - May 23, 2018

Phoenix Tears announced this week that the company has entered a distribution agreement to introduce its Rick Simpson CBD Oil products to hundreds of 7-Eleven stores across the…

Cannabis Wheaton to Raise $100 Million by Selling Units
Manufacturing
6 views
Manufacturing
6 views

Cannabis Wheaton to Raise $100 Million by Selling Units

Sam Rosenberg - May 23, 2018

Cannabis Wheaton Income Corp. (TSX.V:CBW)  announced this week that the company has entered into an agreement BMO Capital and a collection of different funding  groups to offer…

Leave a Comment

Your email address will not be published.

Most from this category

%d bloggers like this: